Hematopoietic and Lymphoid System Neoplasm Recruiting Phase 1 / 2 Trials for Ivosidenib (DB14568)

IndicationStatusPhase
DBCOND0132171 (Hematopoietic and Lymphoid System Neoplasm)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesTreatment